The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association

Montpellier, France, September 10, 2019, 5.45 pm (CEST)
Euronext: MEDCL - FR0004065605

At the Combined General Meeting held on September 5, 2019, in Montpellier, shareholders voted to include the MedinCell “Raison d’être” in the company’s articles of association:

“Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives.”

This triple mission has been at the heart of the company’s DNA since its foundation.

“The Annual General Meeting is traditionally an important moment for MedinCell, which include among its shareholders most of its current and former employees,” said Christophe Douat, CEO of MedinCell. “This year, we had the pleasure of welcoming all those who have joined us since the IPO, both institutional and individual. The interests of both are aligned and intrinsically linked to the success of our mission as a humanist pharma, to the preservation of our business model, where all employees are shareholders, and to the sustainability of MedinCell. This mission is at the heart of our success and unites the talent from all over the world that makes up MedinCell’s team. Its inclusion in the Articles of Association is a fundamental act.”

MedinCell shareholders also adopted all of the proposed resolutions, with the exception of the 22nd resolution, in accordance with the recommendation of the Management Board.

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimetres, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

www.medincell.com